Abstract：
Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic therapies with radiotherapy is therefore challenging. Given this rapid, transformative change in breast cancer multimodal management, the multidisciplinary community must unite to ensure optimal, safe, and equitable treatment for all patients. The aim of this collaborative group of radiation, clinical, and medical oncologists, basic and translational scientists, and patient advocates was to: scope, synthesise, and summarise the literature on integrating novel drugs with radiotherapy for breast cancer; produce consensus statements on drug-radiotherapy integration, where specific evidence is lacking; and make best-practice recommendations for recording of radiotherapy data and quality assurance for subsequent studies testing novel drugs.
摘要：
乳腺癌的新型全身疗法正在迅速应用于临床实践。与传统化疗相比，这些药物通常具有不同的作用机制和副作用。支持改变实践的临床试验集中在正在研究的系统疗法上，因此，关于放射治疗的数据很少。因此,这些新的全身疗法与放射疗法的整合是具有挑战性的。鉴于这种快速，乳腺癌多模式管理的变革，多学科社区必须团结起来，确保最佳状态，安全,以及对所有患者的公平待遇。这个合作辐射小组的目标是，临床,和医学肿瘤学家，基础和翻译科学家，耐心的倡导者是：范围，合成，并总结了乳腺癌新药物与放疗整合的文献;产生关于药物-放疗整合的共识声明，缺乏具体证据的地方；并为记录放射治疗数据和后续测试新药的质量保证提出最佳实践建议。
